metastatic/advanced - esophageal cancer (mEC) | |
mEC - 2nd line (L2) | |
nivolumab based treatment | |
nivolumab alone | ATTRACTION-3 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -